Non Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line - Immunotherapy

No Prior Therapy With PD-1/PD-L1

- LUN0085
  - Phase II
  - Pembrolizumab in Metastatic Non-Squamous NSCLC
  - Examining Circulating Tumor DNA Levels
  - PI: Neal Stanford
  - 1st Priority

- LUN0093
  - Phase III
  - NKTR-214 + Nivolumab in Select Locally Advanced or Metastatic Solid Tumor Malignancies
  - PI: Neal Nekcar
  - 2nd Priority

- VAR0170
  - Phase Ib
  - Cabozantinib (XL184) in Combo w/Atezolizumab in Locally Advanced or Metastatic Solid Tumors
  - PI: Srinivas
  - Pending
  - 3rd Priority

On anti PD-1/anti PD-L1 with response, stable disease or modest progression

- LUN0088
  - Phase II
  - Radical Dose RT with Anti-PD-1/Anti-PD-L1 Immunotherapy in Non-Small Cell Lung Cancer
  - PI: Gensheimer
  - Stanford

Failed Therapy PD-L1

- VAR0170
  - Phase Ib
  - Cabozantinib (XL184) in Combo w/Atezolizumab in Locally Advanced or Metastatic Solid Tumors
  - PI: Srinivas
  - Pending
  - 1st Priority

- ECOGS1400
  - Phase II/III
  - Biomarker in Second Line Therapy of Squamous Cell Lung Cancer (Screening Step)
  - PI: Wakelee
  - ECOG-ACRIN
  - 2nd Priority